We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.30 | 0.68% | 44.24 | 44.47 | 43.728 | 43.87 | 13,247,504 | 00:58:24 |
From May 2019 to May 2024
By Dave Sebastian
Bristol-Myers Squibb Co. (BMY) on Thursday set its financial outlook for 2020 as it reported fourth-quarter loss and higher sales.
The pharmaceutical company expects 2020 revenue of $40.5 billion to $42.5 billion both on a reported and adjusted basis.
It sees earnings of 75 cents a share to 95 cents a share, or $6 a share to $6.20 a share on an adjusted basis.
The company said its guidance for 2020 and 2021 includes the effect of the Celgene acquisition and the Otezla divestiture.
Shares rose 1.1% in premarket trading.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
February 06, 2020 07:39 ET (12:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
